Multiple system atrophy, parkinsonian type
Synonyms: MSA, parkinsonian type | MSA-p
Multiple system atrophy parkinsonian type (MSA-p) is a form of multiple system atrophy (MSA; see this term) with predominant parkinsonian features (bradykinesia rigidity irregular jerky postural tremor and postural instability).
Data from Orphanet are used to provide information on a disease's name, synonym(s), and overview.
Reference: Access aggregated data from Orphanet at Orphadata.
Orphadata: Free access data from Orphanet. © INSERM 1999. Available on http://www.orphadata.org. Data version May 2024
Newly diagnosed with
Multiple system atrophy, parkinsonian type?
Our RARE Concierge Services Guides are available to assist you by providing information, resources and connections as you navigate your rare disease journey.
Advocacy Organizations
COMBINEDBrain Inc
COMBINEDBrain is a consortium for outcome measures and biomarkers for neurodevelopmental disorders. We are collaborating to cure rare, non-verbal brain disorders.
Dysautonomia Support Network
Dysautonomia Support Network’s Mission is to provide a Community that Empowers and Supports those impacted by dysautonomia to live their best lives. DSN provides support through community, virtual support group meetings and amazing resources such as Handouts, Handbooks and our Dyscovery Education video series.
Mission MSA
Mission MSA is devoted to improving quality of life and building hope for people affected by multiple system atrophy through support, education, research, and community.
Moonshots for Unicorns
Curing single-gene disorders
National Ataxia Foundation
To accelerate the development of treatments and a cure while working to improve the lives of those living with Ataxia.
Project CASK
To fund research for treatment and/or a cure for CASK Gene Disorder
The Assistance Fund
The Assistance Fund (TAF) is an independent charitable patient assistance organization that helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles, and other health-related expenses. We currently manage more than 80 disease programs, each of which covers all FDA-approved treatment for the disease named in the program. Since 2009, TAF has helped nearly 180,000 people access critical treatment for life-threatening, chronic, and rare diseases.
Clinical Trials
For a list of clinical trials in this disease area, please click here.